On Friday, Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration. The trial investigated the safety ...

LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral ...

WEDNESDAY, Sept. 11, 2024 (HealthDay News) -- An experimental weight-loss pill appears to help people quickly shed pounds, a new study says. People who took the drug amycretin lost up to 13% of ...

Amycretin differs from other drugs though in also mimicking a second hormone, amylin, which is responsible for helping to regulate blood sugar levels and slowing gastric emptying, prompting the ...

The results show that amycretin led to "remarkable reductions in body weight over only 12 weeks," the research team led by Agnes Gasoirek, a senior clinical pharmacology specialist at Novo Nordisk ...

PLAINSBORO, N.J., June 20, 2025 /PRNewswire/ -- Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment designed to ...

Amycretin also works slightly differently than Eli Lilly’s Zepbound and Viking Therapeutics’ experimental VK-2735, which target GLP-1 and GIPR receptors. Following the release of the trial results, ...

Amycretin is being developed for subcutaneous and oral administration. Shares of this Denmark-based company gained 2.95% on June 12, following the announcement.

Subcutaneous amycretin phase 1 b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was published in The Lancet and presented at the American ...